Biotech Values

[DewDiligence]

CNAT reverse-merges into Histogen:

https://www.globenewswire.com/news-release/2020/01/28/1976385/0/en/Conatus-Pharmaceuticals-and-Histogen-Enter-into-Definitive-Merger-Agreement.html

Conatus Pharmaceuticals...and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company will operate under the name Histogen, Inc., is expected to trade on the Nasdaq Capital Market under a new ticker symbol still to be determined and will focus on advancement of its patented technology for dermatological and orthopedic indications.

…[Histogen’s] lead product candidate, HST 001 or Hair Stimulating Complex (HSC), is a minimally-invasive treatment to promote new hair growth in patients with male pattern hair loss… In addition, Histogen is developing HST 002, a human-derived collagen and extracellular matrix dermal filler, and HST 003, an extracellular matrix scaffold for the treatment of articular cartilage defects. Histogen expects all three product candidates to reach clinical and regulatory inflection points in 2020.

…Under the terms of the merger agreement, pending stockholder approval of the transaction, …Histogen stockholders will receive newly issued shares of Conatus common stock. …current Conatus stockholders will collectively own approximately 26%, and Histogen stockholders will collectively own approximately 74%, of the combined company on a fully-diluted basis…

CNAT's Emricisan program in liver diseases was terminated in Jun 2019 after multiple clinical failures (#msg-149568025).